Cyclomics Overview
Pro stress-test →Cyclomics is a Dutch startup founded in 2018 by scientists of UMC Utrecht, transforming cancer care by enabling faster and more reliable diagnoses, particularly in cancer recurrence detection. The company's CyclomicsSeq consensus sequencing approach improves Oxford Nanopore sequencing quality by 60-fold, enabling detection of rare mutations in blood of cancer patients.
Strategic Profile
Pro stress-test →Cyclomics has developed cutting-edge technology for detecting circulating tumor DNA using 3rd generation Nanopore sequencers, enabling fast, low-cost, point-of-care sequencing with nearly 100% accuracy to detect single ctDNA molecules. The company launched its services branch, expanding its technology and expertise into life sciences, biotechnology, genomics, and clinical diagnostics.
Competitive Landscape
Pro stress-test →Cyclomics serves hospitals and cancer treatment centers requiring reliable diagnostic tools. Direct competitors include Guardant Health and Foundation Medicine in ctDNA-based cancer monitoring, while broader competitors span liquid biopsy platforms (Illumina, BGI) and genomics diagnostics companies (Tempus, Invitae). Cyclomics differentiates through proprietary rolling circle amplification-based nanopore sequencing and faster turnaround (90-minute tumor classification capability).
Industry Context
Cyclomics operates in Liquid biopsy cancer diagnostics.
Key facts
Founded: 2018 · Headquarters: Utrecht, Netherlands · Employees: N/A · Revenue: N/A · Market cap: N/A